nab-paclitaxel

Overview

Nab-paclitaxel (Abraxane; nanoparticle albumin-bound paclitaxel) is an albumin-formulated taxane that stabilizes microtubules and arrests cells in G2/M. The albumin binding improves solubility and tumor penetration compared to solvent-based paclitaxel. In combination with gemcitabine, it is a standard first-line regimen for metastatic pancreatic adenocarcinoma.

Evidence in the corpus

  • KRASG12R-mutant PAAD patients showed enrichment among those receiving neoadjuvant chemotherapy including gemcitabine + nab-paclitaxel followed by resection (32.7% vs 17.9% for KRASG12D, p=0.094), suggesting possible allele-specific chemosensitivity (though this may also reflect selection of borderline-resectable cases) PMID:39214094.
  • Gemcitabine/nab-paclitaxel was used in 37% of the curated 1,480-patient MSK PDAC cohort as a dominant first-line regimen; chemotherapy backbone choice between gemcitabine/nab-paclitaxel and FOLFIRINOX was not significantly associated with overall survival in 304 metastatic chemotherapy-treated patients PMID:39753968.
  • Cited as an ongoing investigational concurrent regimen combined with SBRT in unresectable locally advanced PAAD (NCT02318095); no efficacy data available in this review PMID:27826200

Resistance mechanisms

  • No specific nab-paclitaxel resistance mechanisms reported in the corpus at this time.

Cancer types (linked)

  • PAAD — pancreatic adenocarcinoma; dominant first-line regimen (37% of MSK curated cohort) in combination with gemcitabine.

Sources

  • PMID:39214094 — McIntyre et al. 2024, Cancer Cell. KRAS allele-specific PDAC outcomes; gemcitabine/nab-paclitaxel enrichment in KRASG12R neoadjuvant patients.
  • PMID:39753968 — Varghese et al. 2025, Nature Medicine. MSK PDAC clinicogenomic landscape; gemcitabine/nab-paclitaxel as standard first-line regimen.
  • PMID:27826200 — Tchelebi et al. 2016, Semin Radiat Oncol. SBRT in pancreatic cancer review; gemcitabine + nab-paclitaxel + SBRT cited as investigational combination (NCT02318095).

This page was processed by entity-page-writer on 2026-05-15.